CALC trial: Aprepitant for the treatment of cough in lung cancer

INTERVENTION: Patients will receive 3 days treatment with aprepitant/placebo at standard doses: 125mg D1, 80mg D2 and 80mg D3 followed by 3 days washout period and 3 further days of aprepitant/placebo at standard doses. CONDITION: Topic: National Cancer Research Network; Subtopic: Lung Cancer; Disease: Lung (small cell), Lung (non‐small cell) ; Cancer ; Malignant neoplasm of bronchus and lung PRIMARY OUTCOME: Daytime ambulatory cough monitoring; Timepoint(s): Baseline, D3 and D9 SECONDARY OUTCOME: 1. Biomarker Analysis; Timepoint(s): Day 3 and Day 9; 2. Cough Severity Visual Analogue Scale score; Timepoint(s): Baseline, Day 3 and Day 9; 3. Manchester Cough in Lung Cancer Scale score; Timepoint(s): Baseline, Day 3 and Day 9 INCLUSION CRITERIA: 1. Patients willing and able to give consent for participation in the trial 2. Male or female aged 18 years or above 3. WHO PS 02 4. Diagnosed with lung cancer 5. Able and willing to participate in and comply with the trial schedule 6. Persistent cough >= 4 weeks 7. Not on anticancer therapy 8. No anticancer therapy planned to commence for the duration of the trial participation